| About the author: |
Godovan V. V., Ostapchuk E. V. |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The effect of CYP2E1 gene polymorphisms on the efficiency of the treatment of chronic hepatitis C by peginterferon+ribavirin was stadied in 33 patients. Among them genotype DD by polymorphism CYP2E1*6 had 24 (72,7 %) patients, genotype CD - 9 (27,3%) patients.
Genotype CC was not revealed. Patients with genotype CD more often had early and rapid virological responses compared to the patients with genotype DD (respectively 88,9% and 45,8 %, p = 0,026). Patients with genotype CD restored the level of serum alanine aminotransferase faster (after 12 weeks of treatment) than the patients with genotype DD.
Treatment of the patients with chronic hepatitis C with peginterferon and ribavirin was more effective if they had genotype CD.
|
| Tags |
chronic hepatitis C, gene CYP2E1, genetic polymorphisms |
| Bibliography |
- Блюм Х. Е. Гепатит С: современное состояние проблемы / Х. Е. Блюм // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2005. – Т. 15, № 1. – С. 20-25.
- Кукес В. Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты / В. Г. Кукес. – М.: Реафарм, - 2004. – 203 с.
- Лакин К. М. Биотрансформация лекарственных веществ / К. М. Лакин, Ю. Ф. Крылов. – М.: Медицина, - 1981. – 193 с.
- Carriere V. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype / V. Carriere, F. Berthou, S. Baird [et al.] // Pharmacogenetics. – 1996. – Vol. 6. – Р. 203–211.
- Clinical Practice Guidelines: Management of hepatitis C virus infection // J. Hepatol. – 2011. – Vol. 55. – P. 245–264.
- Ferenci P. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response / P. Ferenci, H. Laferl, T. M. Scherzer [et al.] // Gastroenterology. – 2008. – Vol. 135, № 2. – Р. 451–458.
- Hayashi S. Genetic polymorphisms in the 5-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene / S. Hayashi, J. Watanabe, K. Kawajiri // J Biochem. – 1991. – Vol. 110. – Р. 559–565.
- Hadziyannis S. J. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose / S. J. Hadziyannis, H. Sette, T. R. Morgan [et al.] // Ann Intern Med. – 2004. – Vol. 140. – Р. 346–355.
- Kato S. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk / S. Kato, P. G. Shields, N. E. Caporaso [et al.] // Cancer Res. – 1992. – Vol. 1, № 52(23). – Р. 6712–6715.
- McHutchison J. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection / J. McHutchison, E. Lawitz, M. Shiffman [et al.] // N. Engl. J. Med. – 2009. – Vol. 361. – Р. 580–593.
- Matteo R. Economic Assessment of an Anti-HCV Screening Program in Italy / R. Matteo, S. Coretti, A. Gasbarrini [et al.] // Value in health. – 2013. – Vol. 16. – Р. 965– 972.
- Persson I. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer / I. Persson, I. Johansson, H. Bergling [et al.] // FEBS Lett. – 1993. – Vol. 319. – Р. 207–211.
- Ramaiah S. K. Cytochrome P4502E1 induction increases thioacetamide liver injury in diet-restricted rats / S. K. Ramaiah, U. Apte, H. M. Mehendale // Drug Metab Dispos. – 2001. – Vol. 29. – Р. 1088-1095.
- Stephens E. A. Ethnic variation in the CYP2E1 gene: polymorphismanalysis of 695 African-Americans, European-Americans and Taiwanese / E. A. Stephens, J. A. Taylor, N. Kaplan [et al.] // Pharmacogenetics. – 1994. – Vol. 4. – Р. 185–192.
- Wong J. B. Estimating future hepatitis C morbidity, mortality and costs in the United States / J. B. Wong, G. M. McQuillan, J. G. McHutchison [et al.] // Am J Public Health. –2000. – Vol. 90, № 10. – Р. 1562–1569.
- Wang S. M. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations / S. M. Wang, A. P. Zhu, D. Li [et al.] // J. Hum. Genet. – 2009. – Vol. 54. – Р. 372–375.
|
| Publication of the article |
«World of Medicine and Biology» №2(44), 2014 year, 026-029 pages, index UDK 616 |
